STM JOURNALS

Research & Reviews: A Journal of
Microbiology & Virology

ISSN: 2230-9853 (Online)
ISSN: 2349-4360 9(Print)
Volume 16, Issue 2, 2026
May–August
DOI (Journal): 10.37591/RRJOMV

http://medicaljournals.stmjournals.in/index.php/RRJoMV/index

Review RRJOMV

India's Pioneering Advancements in Vaccinology: Challenges and Milestones – Part 2

Maitry Goel[1], Vibha Gupta[2,*],

Abstract

India has become a global leader in vaccinology, playing a vital role in developing, producing, and distributing vaccines that protect millions of lives. By embracing advances in molecular immunology, recombinant antigen technology, and virus-like particle (VLP) platforms, the country has created affordable vaccines against major diseases, including poliovirus, rotavirus, and SARS-CoV-2. National initiatives, like Mission Indradhanush and Vaccine Maitri, have helped expand immunization coverage, improve public health, and share vaccines with countries in need, reflecting India's commitment to both national and global health. The development of homegrown vaccines, such as Shanvac-B, showcases how cutting-edge biotechnology can be translated into practical solutions that make a real difference in people's lives. Strong regulatory frameworks, including the New Drugs and Clinical Trials Rules (2019) and rigorous chemistry, manufacturing, and controls (CMC) standards, ensure that every vaccine is safe, effective, and capable of generating a strong immune response. Innovations in adjuvants, high-yield production methods, and public–private collaborations have further strengthened India's position in global immunization efforts. With experience in large-scale vaccination drives, research on novel vaccine platforms, and efficient distribution systems, the country is well-prepared to respond swiftly to new health threats. As infectious diseases continue to emerge and public health challenges evolve, India's dedication to scientific innovation, strategic planning, and international collaboration will remain essential to safeguard communities, enhance long-term resilience, and ensure a healthier future for people both within the country and around the world.

Keywords: Immunogenicity, Mission Indradhanush, SARS-CoV-2, Shanvac-B, Vaccine Maitri

INTRODUCTION

Vaccination represents a transformative achievement in contemporary medicine, significantly altering the trajectory of global health by markedly reducing the incidence and mortality associated with infectious diseases. The discipline of vaccinology is inherently interdisciplinary, encompassing immunology, molecular biology, epidemiology, and public health policy to enable the systematic development and strategic distribution of immunoprophylactic interventions. This scientific framework is further integrated with socio-political and logistical considerations that facilitate widespread immunization and herd immunity.

***Author for Correspondence**
Vibha Gupta
E-mail: vibha.gupta@mail.jiit.ac.in

[1]Student, Department of Biotechnology, Jaypee Institute of Information Technology, Sector 62, Noida, Uttar Pradesh, India.
[2]Professor, Department of Biotechnology, Jaypee Institute of Information Technology, Sector 62, Noida, Uttar Pradesh, India.

Received Date: December 09, 2025
Accepted Date: January 04, 2026
Published Date: January 20, 2026

Citation: Maitry Goel, Vibha Gupta,. India's Pioneering Advancements in Vaccinology: Challenges and Milestones – Part 2. Research & Reviews: A Journal of Microbiology and Virology. 2026; 16(2): 1–21p.

In recent decades, India has positioned itself as a critical stakeholder in the global vaccinology landscape – not only as a leading manufacturer but also as an emerging center for innovation. The nation's robust network of biomedical research institutions, biotechnology enterprises, and translational research collaborations underscores its evolving capacity to advance vaccine candidates from conceptualization to clinical application. This trajectory signifies a strategic transition from a volume-centric production model to one characterized by research-driven innovation and

© STM Journals 2026. All Rights Reserved

global health leadership. Consequently, India is now recognized for its pivotal role in ensuring accessible, affordable, and timely vaccine solutions for both domestic and international populations.

India's engagement in vaccine research can be traced to the colonial period, when indigenous smallpox inoculation practices preceded formal Western medical approaches. The establishment of the Haffkine Institute in 1899, spearheaded by Waldemar Haffkine, marked a seminal advancement in institutionalized vaccine research. Haffkine's pioneering development of cholera and plague vaccines laid the scientific foundation for sustained vaccine innovation and positioned India as a critical node in global immunization efforts. From these foundational milestones, India has transitioned from a recipient of imported technologies to a self-sufficient and globally competitive developer of advanced immunological solutions.

This evolution parallels the broader historical arc of vaccinology, which began with Edward Jenner's introduction of the smallpox vaccine in 1798. The subsequent development of vaccines against typhoid, cholera, and plague, as well as the formulation of diphtheria and tetanus toxoids during the 19th and early 20th centuries, marked the consolidation of vaccination as a cornerstone of public health. The mid-20th century introduced purified protein and polysaccharide-based vaccines, paving the way for recombinant DNA technologies that enabled the creation of vaccines against hepatitis B and HPV [1].

India's trajectory has mirrored and contributed to these global advancements. Critical institutions, such as the National Institute of Virology and the National Institute of Immunology, have spearheaded research on vaccines for diseases like polio and tuberculosis. The launch of the UIP in 1985 represented a strategic public health initiative aimed at broadening vaccine coverage nationwide. Indigenous vaccine innovations, such as the Oral Polio Vaccine and the indigenously developed rotavirus vaccine (Rotavac®), were instrumental in India's eradication of poliomyelitis by 2014.

In the 21st century, India demonstrated its global leadership during the COVID-19 pandemic through the rapid development and deployment of indigenous vaccines such as Covaxin by Bharat Biotech and the licensed production of Covishield by the Serum Institute of India in partnership with AstraZeneca and Oxford University. Currently, India accounts for over 60% of global vaccine supply and is increasingly recognized for advancing next-generation technologies, including mRNA-based platforms and thermostable formulations tailored for low-resource settings. This shift from dependence on imported vaccines to pioneering technological advancement underscores India's central role in shaping global immunization strategies and promoting equitable health outcomes [2].

Market dynamics further reflect India's expanding influence. The Indian vaccine market is projected to reach a valuation of USD 1.31 billion by 2025, with a compound annual growth rate (CAGR) of 0.09% expected through 2029. Although the United States is anticipated to lead in revenue generation globally (USD 29.97 billion in 2025), India's growth is driven by its burgeoning population, enhanced public awareness, and proactive government policies supporting immunization. This continued trajectory positions India as an indispensable contributor to both the science and practice of vaccinology, with its sustained efforts poised to drive future innovations in global health [3].

VACCINE DEVELOPMENT, CLINICAL ASSESSMENT, AND AUTHORIZATION PROCEDURE

Vaccine development is a highly intricate and multi-phased translational process that integrates fundamental research, preclinical evaluations, and clinical investigations, all governed by stringent regulatory frameworks to ensure immunogenic efficacy and public safety. This pathway – from antigen discovery to licensure – relies on a rigorous sequence of experimental validations designed to demonstrate that the vaccine candidate elicits a robust immune response without introducing significant risk to the recipient population. The development pipeline encompasses antigen identification, in vivo and in vitro safety testing, phased human clinical trials, and post-marketing surveillance [4].

© STM Journals 2026. All Rights Reserved

- *Exploratory Stage*: The initial stage involves fundamental laboratory-based research aimed at identifying suitable antigenic targets – such as inactivated pathogens, virus-like particles, or attenuated organisms – capable of eliciting an adaptive immune response. This phase typically spans 2–4 years and is focused on the screening and optimization of immunogenic candidates through in vitro assays and computational modelling.
- *Pre-Clinical Stage*: In the preclinical phase, the selected vaccine formulations undergo extensive testing in animal models or ex vivo systems to evaluate immunogenicity, toxicity profiles, and dose optimization. Challenge studies are often conducted to test protective efficacy by exposing immunized animals to the target pathogen. This phase, lasting approximately 1–2 years, is critical for advancing candidates to first-in-human trials.

Clinical Trial Phases

- *Phase I:* Conducted on a small cohort (typically fewer than 100 individuals), this phase aims to assess preliminary safety, tolerability, and immunogenic response, often under tightly controlled environments. It typically concludes within several months.
- *Phase II:* This stage expands the participant base to several hundred volunteers to refine the dosage, monitor short-term adverse events, and further validate immunogenic outcomes. This phase may span up to two years.
- *Phase III:* Encompassing 1,000–3,000 subjects, Phase III trials are randomized, double-blind, and placebo-controlled studies aimed at establishing the vaccine's clinical efficacy and safety across diverse populations. These studies often last 1–4 years and are critical for regulatory submissions. Historically, only 25–30% of vaccine candidates successfully progress through this phase.
- *Phase IV:* Post-marketing surveillance, or Phase IV, is undertaken after the vaccine is licensed. It involves long-term safety monitoring in real-world populations to identify rare adverse events, evaluate effectiveness, and ensure sustained safety through pharmacovigilance mechanisms.
- *Regulatory Compliance:* In India, vaccine trials must follow the Drug and Cosmetic Act of 1940 and Schedule Y regulations. Sponsors must submit detailed documentation of the vaccine's development and clinical trial results. The DCGI oversees the approval process, ensuring vaccines meet safety and efficacy standards, with mandatory reporting of adverse events [4].

REGULATORY FRAMEWORK FOR VACCINE DEVELOPMENT IN INDIA

Vaccine licensure in India follows a distinct and rigorous regulatory pathway, separate from conventional pharmaceutical drugs, with multiple oversight bodies involved in the governance and enforcement of clinical safety and ethical compliance.

- *Legislative Oversight and Regulatory Authorities:* The Central Drugs Standard Control Organization (CDSCO), under the aegis of the Ministry of Health and Family Welfare (MoHFW), is the apex body responsible for the regulation of biologics, including vaccines. The Drug Controller General of India (DCGI), acting as the Central Licensing Authority, supervises the approval, import, and clinical evaluation of vaccines under the *Drugs and Cosmetics Act (1940)* and the associated *Rules (1945)* [5, 6]. As per the *New Drugs and Clinical Trials Rules (2019)*, the DCGI evaluates submissions in consultation with statutory bodies, such as the Drug Technical Advisory Board (DTAB) and the Drugs Consultative Committee, ensuring compliance with national and international standards [7].
- *Policy and Scientific Advisory Mechanisms:* Policy decisions surrounding vaccine introduction into national immunization programs are informed by the DTAB and the National Immunization Technical Advisory Groups (NITAGs), which offer evidence-based recommendations tailored to country-specific epidemiological priorities [8].
- *Clinical Trial Governance:* The Indian Council of Medical Research (ICMR), functioning under the Department of Health Research (MoHFW), enforces adherence to *Good Clinical Practice (GCP)* guidelines and bioethical principles during vaccine trials [9].
- *Ethical Oversight Mechanism:* All human studies are subject to review by an Ethics Committee (EC) composed of a minimum of seven multidisciplinary experts. The EC is tasked with

© STM Journals 2026. All Rights Reserved

safeguarding participant rights, reviewing serious adverse events (SAEs), validating informed consent protocols, and ensuring investigator competence. As mandated by *Rule 7*, ethics committees must be registered prior to trial initiation (via Clinical Trial-04), with approvals valid for a two-year term (Clinical Trial-06) [10, 11]. The EC also holds authority to suspend or terminate trials should participant safety be compromised.

Vaccination remains a cornerstone of India's public health strategy, playing an instrumental role in mitigating the burden of communicable diseases and enhancing population health outcomes. The expansive implementation of immunization programs, such as the Universal Immunization Programme (UIP), has significantly reduced morbidity and mortality from vaccine-preventable diseases. Moreover, India's progressive investment in research and innovation has amplified vaccine accessibility and catalyzed socioeconomic advancement. Thus, India's vaccine development landscape is supported by robust scientific infrastructure, stringent regulatory mechanisms, and a growing emphasis on innovation and equity. Continued advances in novel platforms – such as mRNA and thermostable formulations – combined with comprehensive ethical and regulatory compliance, will remain pivotal in ensuring sustainable, safe, and globally relevant vaccine solutions.

NATIONAL IMMUNIZATION FRAMEWORKS AND TARGETED DISEASE ERADICATION STRATEGIES

Robust immunization frameworks constitute a fundamental pillar of public health infrastructure, significantly contributing to the prevention of infectious disease outbreaks and enhancing global health preparedness. Comprehensive immunization strategies integrate routine national vaccination programs, disease-specific eradication initiatives, and multilateral global partnerships to ensure broad-spectrum vaccine accessibility and efficacy. National immunization efforts primarily aim to deliver routine vaccination coverage, thereby safeguarding population immunity and minimizing the incidence of vaccine-preventable diseases. In parallel, targeted eradication campaigns are designed to interrupt transmission cycles of high-burden pathogens, focusing on complete elimination through intensive surveillance and high-coverage immunization drives. At the global level, strategic alliances among international organizations, research institutions, and governmental bodies facilitate collaborative vaccine development, resource sharing, and the equitable distribution of immunization tools. These partnerships address systemic disparities and catalyze innovation, particularly in low- and middle-income countries. Together, these multilayered strategies enhance immunological resilience, reduce disease prevalence, and contribute to a more robust and responsive global health ecosystem capable of withstanding future infectious threats.

Universal Immunization Programme (UIP)

The Universal Immunization Programme, launched in 1985 under the National Health Mission, represents one of India's most ambitious and enduring public health interventions, aimed at mitigating the burden of vaccine-preventable diseases across the population spectrum [12]. Through the provision of free immunization services, the programme has significantly contributed to reductions in childhood morbidity and mortality, while reinforcing national and global disease elimination efforts.

Central to the programme is the National Immunization Schedule, a standardized framework that delineates the type and timing of vaccine administration to optimize immunogenicity and ensure lifelong protection [13] as illustrated in Figure 1. This structured delivery model encompasses the routine immunization of neonates, infants, children, and at-risk adults, thereby promoting early-life immunity and herd protection. The programme currently includes vaccination against twelve critical infectious diseases: tuberculosis, diphtheria, pertussis, tetanus, poliomyelitis, measles, hepatitis B, rotavirus, rubella, Japanese encephalitis, pneumonia, and pneumococcal infections. In alignment with global evidence and World Health Organization recommendations, the immunization portfolio has been progressively expanded to incorporate newer antigens such as the Inactivated Polio Vaccine, Rotavirus Vaccine, Measles–Rubella vaccine, adult Japanese Encephalitis vaccine, and the Pneumococcal

© STM Journals 2026. All Rights Reserved

Conjugate Vaccine [14]. To address geographical and socioeconomic disparities in vaccine delivery, the Indian government has augmented its cold chain and supply logistics and introduced a targeted intervention titled Mission Indradhanush to improve immunization rates in under-served districts. This initiative has been pivotal in reaching vulnerable populations, including tribal, migratory, and remote communities, with life-saving vaccines.

In 2022, a budgetary allocation of 7,234 crore Indian Rupees was dedicated to supporting programme operations, procurement, and infrastructure [15], underlining the state's continued commitment to comprehensive immunization. Notably, the programme's inclusive framework ensures vaccine availability for all residents, including non-citizens, thereby reinforcing India's contribution to the global health agenda on equitable immunization access. By integrating scientific rigor with policy foresight, the Universal Immunization Programme continues to serve as a cornerstone of India's disease prevention strategy. Its sustained expansion and adaptive capacity position it as a model of effective immunization governance, contributing substantially to regional disease control, outbreak prevention, and the realization of Sustainable Development Goals related to health and well-being.



Figure 1. National immunization schedule of India – Timeline for Pregnant Women, Infants, and Children.

Pulse Polio Immunization (PPI) Campaign

Poliomyelitis, a highly infectious viral disease primarily afflicting children under five, has posed a significant global health challenge due to its potential to cause irreversible paralysis and mortality. In alignment with the World Health Organization's Global Polio Eradication Initiative (GPEI) launched in 1988, India initiated the Pulse Polio Immunization (PPI) campaign in 1995, aiming for comprehensive immunization coverage through repeated mass vaccination and door-to-door outreach, particularly targeting hard-to-reach and underserved populations [16].

© STM Journals 2026. All Rights Reserved

India's polio vaccination efforts commenced earlier under the Expanded Programme on Immunization (EPI) in 1972; however, substantial gains in vaccination coverage were realized post-1985 with the implementation of the Universal Immunization Programme (UIP), which systematically integrated polio immunization into the national vaccine schedule. The strategic incorporation of National Immunization Days (NIDs) targeted all children below five years, facilitating high-volume, synchronized immunization drives that drastically curtailed poliovirus transmission.

By 2011, India successfully documented the last case of wild poliovirus, marking a pivotal achievement in global public health [16]. This accomplishment resulted from a multifaceted approach that combined the establishment of fixed vaccination booths, maintenance of a robust cold chain infrastructure ensuring vaccine potency, and meticulous monitoring of immunization coverage. Community engagement was paramount, with mobilization of volunteers and local leaders facilitating awareness campaigns and combating vaccine hesitancy through tailored messaging disseminated via television, radio, and mobile communication platforms.

Despite this success, the campaign confronted notable challenges. Environmental factors, such as endemic poor sanitation, high prevalence of diarrheal diseases, and open defecation reduced oral polio vaccine (OPV) efficacy, necessitating repeated dosing to elicit adequate immunity. Furthermore, vaccine skepticism fueled by misinformation – ranging from unfounded concerns about infertility to cultural and religious objections – resulted in resistance within select communities, delaying eradication timelines.

Post-eradication surveillance revealed sporadic incidences of vaccine-derived poliovirus (VDPV), underscoring the necessity for continuous epidemiological vigilance and adaptive immunization strategies even after elimination of wild poliovirus circulation. India's comprehensive PPI campaign exemplifies a successful integration of immunological science, public health logistics, and community participation, reinforcing the critical importance of sustained vaccination efforts, real-time surveillance, and culturally sensitive health communication in the global endeavor to eradicate poliomyelitis [17].

Poliomyelitis (polio) is a highly contagious viral disease that primarily affects children under five years of age. In response to the global initiative to eradicate polio, India launched the Pulse Polio Immunization (PPI) campaign in 1995. This large-scale vaccination program aimed to reach every child, especially in remote and underserved areas, through mass immunization drives and door-to-door campaigns. The campaign was part of the broader Global Polio Eradication Initiative launched by the World Health Organization (WHO) in 1988. By 2011, India reported the last case of wild poliovirus, marking a significant milestone [16]. India's initial efforts at polio vaccination began in 1972 with the Expanded Programme on Immunization (EPI). However, significant improvements were made after the introduction of the Universal Immunization Programme (UIP) in 1985, which aimed for nationwide vaccination coverage. Over time, the program evolved, incorporating polio-specific immunization activities, especially National Immunization Days (NIDs), where all children under five were targeted for vaccination. These efforts resulted in a sharp decline in polio cases, with only 42 reported cases by 2010.

This Program aimed to achieve 100% coverage and utilized a multi-pronged strategy. Key components included setting up vaccination booths across the country, ensuring a steady vaccine supply through cold chain management, and actively tracking vaccination coverage. The program emphasized community mobilization, with volunteers helping to spread awareness and ensure participation. Publicity through mass media, including TV, radio, and mobile networks, was instrumental in reaching remote populations and dispelling myths about polio vaccination. Despite the success, the program faced numerous challenges. One significant issue was the reduced effectiveness of polio vaccines in certain regions due to environmental factors like poor sanitation, diarrhea, and open defecation. These conditions necessitated multiple doses of the vaccine to provide sufficient immunity. Moreover, misinformation about the vaccine, including fears of infertility or religious objections, led to resistance in some communities, which further delayed progress toward full eradication. While the country

© STM Journals 2026. All Rights Reserved

achieved remarkable success, challenges persisted, including the occurrence of vaccine-derived poliovirus (VDPV) in some cases. These cases, though rare, highlighted the need for continuous surveillance and responsive actions even after the cessation of wild polio. Nonetheless, India's Pulse Polio campaign has been widely regarded as a public health success, showcasing the importance of comprehensive immunization efforts, robust surveillance, and strong community engagement in achieving the goal of disease eradication [17].

Mission Indradhanush

India's Mission Indradhanush (MI), initiated on 25 December 2014 by the Ministry of Health and Family Welfare (MoHFW), represents a pivotal immunization strategy aimed at achieving ≥90% full immunization coverage among children and pregnant women. As part of the National Health Mission (NHM), the initiative focuses on delivering vaccines against eight life-threatening diseases, including diphtheria, pertussis, tetanus, poliomyelitis, measles, childhood tuberculosis, hepatitis B, and Haemophilus influenzae type B (Hib) infections. Region-specific expansion has introduced additional immunogens, such as rotavirus and Japanese encephalitis (JE) vaccines, to address geographically prevalent pathogens [18].

The program strategically identified 201 high-priority districts, encompassing nearly half of the nation's under-immunized population. These districts were primarily concentrated in Uttar Pradesh, Bihar, Rajasthan, and Madhya Pradesh – regions with historically low coverage. Built upon the operational success of the Pulse Polio Immunization model, MI utilizes multi-channel delivery mechanisms, including fixed session sites, outreach sessions, mobile teams, and community-based tracking systems to reach underserved populations. To intensify these efforts, the Intensified Mission Indradhanush (IMI) was launched, with its latest iteration – IMI 5.0 (2023) – marking a comprehensive, nationwide campaign implemented across all districts of India. For the first time, the campaign expanded its age eligibility to include children up to five years, reflecting a broader epidemiological focus. A core objective of IMI 5.0 was to accelerate measles and rubella elimination, in alignment with the WHO South-East Asia Regional Office (SEARO) 2023 targets. Executed in three operational phases from August to October 2023, with extensions into November in selected states, IMI 5.0 achieved substantial coverage. Over 3.46 million children and 650,000 pregnant women were vaccinated in the first two phases alone. Since 2014, the cumulative impact of Mission Indradhanush includes immunization of over 50.6 million children and 12.5 million pregnant women across 11 completed rounds, with the 12th phase currently underway [19].

The campaign's implementation was underpinned by evidence-based microplanning, GIS mapping, intersectoral convergence, and strengthened cold chain infrastructure. Moreover, comprehensive Information, Education, and Communication (IEC) strategies and active participation from community health workers, local leaders, and digital influencers played a critical role in mitigating vaccine hesitancy and enhancing public trust.

Thus, MI and IMI 5.0 exemplify effective large-scale deployment of immunobiologicals, highlighting the integration of epidemiological data, community engagement, and logistical innovation. These programs contribute significantly to reducing the burden of vaccine-preventable diseases, enhancing herd immunity, and strengthening India's preparedness for future infectious disease threats. Their success demonstrates the utility of programmatic surveillance, targeted outreach, and technological integration in advancing public immunization goals.

Vaccine Maitri/Vaccine Friendship

Vaccine Maitri (*Vaccine Friendship*) is a strategic humanitarian initiative launched by the Government of India on 20 January 2021 to facilitate equitable global access to COVID-19 vaccines, particularly among low- and middle-income countries [20]. This program aligns with India's longstanding tradition of medical diplomacy and underscores the nation's status as a key player in global biopharmaceutical manufacturing.

© STM Journals 2026. All Rights Reserved

By 21 February 2022, the initiative had resulted in the delivery of approximately 162.9 million doses to 96 countries [21]. The distribution framework included.

- 14.3 million doses donated directly to 98 countries as a form of bilateral aid.
- 107.1 million doses supplied through commercial agreements with Indian vaccine manufacturers.
- 41.5 million doses provided under the COVAX initiative, a global collaboration co-led by Gavi, CEPI, and the WHO to ensure fair and equitable access to COVID-19 vaccines.

In March 2021, India temporarily suspended exports of the Covishield vaccine – manufactured by the Serum Institute of India – in response to a surge in domestic cases [22]. However, exports resumed in October 2021, as announced by Union Health Minister Dr. Mansukh Mandaviya, once the national supply stabilized [23]. Furthermore, on 27 March 2021, India extended its diplomatic and humanitarian outreach by donating 200,000 doses to the United Nations peacekeeping forces, ensuring vaccine coverage for personnel deployed across various global missions [24, 25]. This initiative is emblematic of how biotechnology, international policy, and health equity can converge during global crises. India's robust vaccine production capacity, regulatory agility, and commitment to multilateral cooperation allowed it to emerge as a pivotal contributor to global immunization efforts during the COVID-19 pandemic. From a biotechnology perspective, *Vaccine Maitri* demonstrates the scalable impact of public–private partnerships, mRNA and viral vector platforms, and cold chain infrastructure, making it a significant case study in global health diplomacy and pandemic preparedness.

Gavi (Vaccine Alliance)

Gavi, the Vaccine Alliance, is a global public–private partnership established in 2000 with the goal of improving access to vaccines in low- and middle-income countries (LMICs). By 2016, it had emerged as a central conduit for global health financing, channeling over half of donor assistance towards immunization programs worldwide [26–28]. Its strategic interventions have helped immunize over 760 million children and are estimated to have prevented more than 13 million deaths, significantly contributing to global reductions in child mortality. Notably, in countries supported by Gavi, coverage of the diphtheria–tetanus–pertussis (DTP3) vaccine rose from 59% in 2000 to 81% by 2019, reflecting its impact on strengthening routine immunization services [29, 30]. Gavi adopts a dynamic financing model that includes pooled procurement, bulk purchasing, price tiering, and long-term supplier agreements. These strategies collectively reduce vaccine prices, ensure sustainable supply chains, and incentivize manufacturers to participate in low-return markets. In addition to procurement, Gavi invests in strengthening healthcare infrastructure, building cold chain systems, training healthcare personnel, and supporting surveillance programs – all of which are vital for the effective delivery of vaccines and rapid response to outbreaks. India plays a dual role in Gavi's framework, both as a recipient and an active contributor. Between 2016 and 2020, the Indian government contributed $7 million to Gavi, reinforcing its commitment to global immunization equity. Simultaneously, the Serum Institute of India – one of the world's largest vaccine manufacturers – has been instrumental in producing cost-effective vaccines that meet Gavi's quality and affordability standards. This synergy between domestic vaccine production and international health partnerships has helped extend immunization coverage across vulnerable populations in developing nations.

Despite its achievements, Gavi has faced criticism regarding its prioritization of newer, costlier vaccines over the broader expansion of essential routine immunizations [31]. Concerns have also been raised about potential conflicts of interest, as several pharmaceutical manufacturers hold positions within the alliance's governance structure, potentially influencing strategic decisions [32]. In response, Gavi has made efforts to enhance transparency and uphold ethical standards in its policymaking processes, while continuing to evolve its immunization strategies in collaboration with stakeholders worldwide [33].

The National TB Elimination Program (NTEP)

The National Tuberculosis Elimination Program (NTEP), previously known as the Revised National Tuberculosis Control Program (RNTCP), was rebranded in 2020 to align with India's ambitious goal

© STM Journals 2026. All Rights Reserved

of eliminating tuberculosis (TB) by 2025, five years ahead of the global Sustainable Development Goal target. The program is structured around the strategic pillars of Detect, Treat, Prevent, and Build (DTPB), emphasizing early case detection, prompt and effective treatment, preventive measures such as contact tracing and infection control, and the development of robust health infrastructure. A key focus of NTEP is diagnostic expansion and accessibility. By 2023, India had established more than 24,500 Designated Microscopy Centers and 6,496 molecular testing laboratories, supporting the large-scale screening of populations at risk. That same year, the program conducted approximately 1.89 crore sputum microscopy tests and 68.3 lakh nucleic acid amplification tests (NAATs), contributing to improved case detection and classification. The treatment success rate has shown consistent improvement, reaching 87.6% in 2023, with dedicated care pathways developed for managing drug-resistant TB and patients with comorbid conditions such as HIV or diabetes.

To address the social determinants of TB and support patient adherence, the government provides comprehensive services free of cost, including diagnostics, drug regimens, and nutritional support. The Nikshay Poshan Yojana, a direct benefit transfer scheme, offers TB patients ₹500 per month to help meet their nutritional needs during treatment. In addition, the Pradhan Mantri TB Mukt Bharat Abhiyaan has mobilized over 1.6 lakh Nikshay Mitras – community donors who voluntarily support TB patients by offering nutritional kits, counseling, or other forms of assistance. This community-driven initiative enhances patient engagement and reduces stigma. Recognizing the importance of private sector participation, NTEP has also fostered strong public–private partnerships. This approach has resulted in a sevenfold increase in TB case notifications from private healthcare providers, who accounted for nearly 33% of all reported TB cases in 2023. These collaborative, patient-centric strategies underscore NTEP's multi-sectoral commitment to innovation, equity, and the elimination of TB in India [34].

The Pradhan Mantri TB Mukt Bharat Abhiyaan (PMTBMBA)

The Pradhan Mantri TB Mukt Bharat Abhiyaan (PMTBMBA), inaugurated on September 9, 2022, by the Hon'ble President of India, represents a strategic enhancement of the national tuberculosis (TB) elimination framework by mobilizing community and corporate participation. This initiative operationalizes a voluntary donor network termed Nikshay Mitras – comprising individuals, corporate entities, institutions, and elected representatives – who provide comprehensive nutritional, psychosocial, and vocational support to TB patients throughout their treatment. As of July 31, 2024, over 160,000 Nikshay Mitras have been registered and actively linked with more than 1.14 million TB patients, facilitating improved treatment adherence and outcomes. Abhiyaan's extensive reach is demonstrated by the distribution of approximately 1.8 million nutritional support kits, underscoring its commitment to addressing the socioeconomic determinants of TB. High-level advocacy involving Governors, Ministers, Members of Legislative Assemblies, and senior bureaucrats has elevated the campaign into a nationwide Jan Andolan (people's movement), reinforcing the Prime Minister's vision for a multi-sectoral, people-centric strategy to eliminate TB by 2025. PMTBMBA complements the National TB Elimination Programme's (NTEP) goals by fostering community ownership, strengthening patient-centered care, and bridging gaps in social support, thereby accelerating India's trajectory toward TB eradication [34].

U Win

The U-WIN Portal represents a transformative advancement in India's immunization landscape, delivering a fully digital and integrated system for tracking and managing vaccinations among pregnant women and children aged 0–17 years within the Universal Immunization Programme. This innovative platform enables beneficiaries to self-register via an intuitive web interface or mobile application, offering personalized immunization schedules and automated reminders via SMS to ensure timely vaccine uptake. Additionally, it provides QR-coded eVaccination Certificates and facilitates the creation of Ayushman Bharat Health Account (ABHA) IDs, promoting seamless integration with broader healthcare services. Available in 11 regional languages, U-WIN significantly enhances accessibility across India's diverse populations. By mid-September 2024, the platform had successfully enrolled over 64 million individuals, coordinated upwards of 10 million vaccination sessions, and

© STM Journals 2026. All Rights Reserved

administered more than 230 million vaccine doses, demonstrating its critical role in improving immunization outreach and health record digitization [35].

This digital intervention complements India's comprehensive immunization strategy, which has consistently advanced public health outcomes through innovation, collaboration, and community engagement. By harnessing technology to optimize vaccine delivery and monitoring, India has strengthened its capacity to prevent vaccine-preventable diseases and move closer to achieving national and global immunization goals. Continued integration of such digital tools, alongside sustained policy support and multisectoral partnerships, positions India as a leader in advancing equitable healthcare access and contributing significantly to worldwide disease prevention efforts.

STRATEGIC APPROACHES TO VACCINE INNOVATION AND PUBLIC HEALTH IMMUNIZATION

India has emerged as a biotechnology powerhouse through its strategic focus on vaccine research, development, and mass immunization programs. By capitalizing on indigenous R&D, scalable biomanufacturing, and public–private collaborations, the nation has successfully developed affordable vaccines addressing both endemic and global infectious diseases. Landmark innovations, such as rotavirus, COVID-19, and typhoid conjugate vaccines, have significantly reduced disease burden while enhancing equitable healthcare access. Furthermore, India's contributions to global vaccination efforts, particularly through GAVI and WHO-led initiatives, reflect its dual role as both a scientific innovator and humanitarian contributor. This comprehensive approach underscores India's growing influence in shaping global health security through biotechnology-led immunization strategies.

Vaccines for Endemic and Childhood Diseases

India has made significant strides in developing prophylactic solutions for endemic and pediatric infectious diseases by leveraging advances in biotechnology and indigenous innovation. The formulation of cost-effective, locally manufactured vaccines has been critical in mitigating the impact of high-burden pathogens such as rotavirus, measles, and Haemophilus influenzae type b (Hib). These immunobiologicals, developed through robust translational research and supported by a mature biopharmaceutical ecosystem, have substantially strengthened pediatric immunity. As a result, India's vaccine initiatives have enhanced national immunization coverage and contributed to the long-term goal of disease elimination in vulnerable populations.

- *Havisure® Indigenously Developed Hepatitis A Vaccine:* Havisure® is a two-dose inactivated Hepatitis A vaccine developed by Indian Immunologicals Ltd (IIL), representing India's first domestically produced vaccine targeting the Hepatitis A virus (HAV). Administered to children aged 12 months and older, with a booster dose after a minimum six-month interval, it is recommended for routine pediatric immunization as well as high-risk groups, including travelers to HAV-endemic areas. Hepatitis A, caused by a non-enveloped, single-stranded RNA virus of the *Picornaviridae* family, spreads primarily via the fecal–oral route, particularly in regions with inadequate sanitation. Clinical manifestations range from mild, self-limiting symptoms to severe liver complications in adults and individuals with hepatic comorbidities. Havisure® addresses a critical gap in local vaccine access by enhancing national self-reliance in HAV prevention, reinforcing public health infrastructure, and contributing to broader disease control strategies [36].
- *Shanvac-B (Shantha Biotechnics) – First Indigenous Hepatitis B Vaccine:* Shanvac-B, developed in 1997 by Shantha Biotechnics, represents a cornerstone in India's biotechnology landscape as the first indigenously engineered recombinant Hepatitis B vaccine. This milestone was achieved using *Pichia pastoris*, a eukaryotic yeast system well-suited for high-yield expression of recombinant proteins. Through recombinant DNA technology, the Hepatitis B surface antigen (HBsAg) was efficiently expressed and purified to produce a vaccine with strong immunogenicity and excellent safety profile. This approach not only demonstrated India's technical capabilities in genetic engineering and protein expression systems but also set a precedent for the development of future recombinant biologics in the country.

© STM Journals 2026. All Rights Reserved

From a public health perspective, Shanvac-B provided a transformative solution to a major disease burden by offering an affordable alternative to expensive imported Hepatitis B vaccines. Prior to its introduction, access to Hepatitis B vaccination was limited, especially in low-income populations. The availability of a cost-effective indigenous vaccine facilitated the integration of Hepatitis B immunization into India's Universal Immunization Programme (UIP), helping reduce the incidence of chronic liver diseases such as cirrhosis and hepatocellular carcinoma. Its wide deployment across pediatric and adult populations significantly contributed to improved population-level immunity and prevention of perinatal transmission.

Importantly, Shanvac-B earned the distinction of being India's first WHO-Geneva pre-qualified Hepatitis B vaccine. This regulatory endorsement validated its adherence to international standards of quality, safety, and efficacy, enabling its inclusion in global procurement programs through agencies like UNICEF and GAVI. The WHO prequalification not only expanded its reach to other developing nations but also positioned India as a credible and self-reliant innovator in the global biopharmaceutical ecosystem. Shanvac-B's success highlighted the potential of Indian biotechnology to deliver affordable, high-impact solutions for both national and international public health needs [37].

PentaVac (Serum Institute of India) – Combination Vaccine for Infants

Pentavac, developed by the Serum Institute of India, is a five-in-one pediatric vaccine designed to protect against Diphtheria, Tetanus, Pertussis, Hepatitis B, and *Haemophilus influenzae* type B (Hib). It reflects a major advancement in vaccine biotechnology, integrating recombinant and conjugate-based components within a single formulation. The Hepatitis B antigen is produced using recombinant DNA techniques in a yeast expression system, while the Hib antigen is conjugated to tetanus toxoid, enhancing immune recognition in infants. This innovative composition not only simplifies immunization schedules but also ensures broad-spectrum protection during early childhood.

Immunologically, Pentavac is crafted to stimulate a robust and long-lasting immune response. The inclusion of both protein toxoids and whole-cell components allows for effective activation of adaptive immunity. The conjugated Hib antigen elicits T-cell-dependent responses, critical for infants who typically show poor responses to unconjugated polysaccharides. The recombinant Hepatitis B antigen maintains high purity and stability, reducing the risk of adverse reactions. This formulation is administered intramuscularly in a series beginning at 6 weeks of age, followed by doses at 10 and 14 weeks, with a booster between 12 to 18 months. Its design reduces the number of separate injections, improving vaccine adherence and reducing stress for both healthcare providers and caregivers.

From a public health standpoint, Pentavac has made a significant impact by expanding the reach of essential immunizations through India's Universal Immunization Programme (UIP). Its affordability, ease of administration, and reduced logistical complexity have contributed to higher vaccination coverage, especially in low-resource settings. By merging multiple vaccines into a single product without compromising efficacy, Pentavac showcases how indigenous biotechnological innovation can support large-scale disease prevention and improve child health outcomes. It remains a prime example of how India's vaccine industry continues to bridge scientific advancement with public health goals [38].

Cervavac (Serum Institute of India) – India's First Indigenous HPV Vaccine

Cervavac, launched by the Serum Institute of India in 2023, is the country's pioneering vaccine against human papillomavirus (HPV), developed using virus-like particle (VLP) technology. This vaccine targets high-risk HPV strains 16 and 18, which are responsible for most cervical, vulvar, vaginal, and anal cancers, while also providing protection against HPV types 6 and 11, the primary causes of genital warts. By employing VLPs that mimic the native viral structure without containing viral DNA, Cervavac stimulates a potent immune response without risk of infection. Its development marks a critical step in making HPV vaccination affordable and widely accessible in India, addressing a significant public health challenge posed by cervical cancer [39].

© STM Journals 2026. All Rights Reserved

Rotavac (Bharat Biotech) – Affordable Rotavirus Vaccine

Rotavac, developed by Bharat Biotech through a collaborative public–private partnership including DBT, PATH, and the Bill & Melinda Gates Foundation, is India's first live attenuated oral rotavirus vaccine aimed at preventing severe diarrheal disease in infants. The vaccine is derived from the naturally occurring Rotavirus 116E strain isolated at AIIMS, New Delhi, and administered in a three-dose schedule starting at six weeks of age. Rotavac's robust stability profile, with a shelf life of up to five years at –20°C and six months at refrigerated temperatures (5°C ±3°C), enhances its utility in diverse climatic conditions. Following extensive Phase 3 clinical evaluation within India, WHO granted prequalification in 2018, enabling its inclusion in immunization programs globally and contributing substantially to the reduction of rotavirus-related infant mortality [40].

The development and implementation of advanced vaccines, such as recombinant Hepatitis B, pentavalent combination vaccines, live attenuated rotavirus vaccines, and VLP-based HPV vaccines, reflect India's rapidly advancing biotechnology sector and vaccine manufacturing capabilities. These immunoprophylactic innovations have significantly lowered disease incidence, hospitalizations, and deaths from infectious diseases, while strengthening the effectiveness of national immunization programs. Furthermore, their recognition and prequalification by global health authorities affirm India's strategic role in enhancing worldwide vaccine security, particularly by improving equitable access to essential vaccines in resource-limited settings across low- and middle-income countries.

COVID-19 Vaccines and Pandemic Response

India's COVID-19 vaccination campaign, initiated on January 16, 2021, epitomizes the nation's dedication to public health and its influential role in global immunization efforts. By March 4, 2023, more than 2.2 billion vaccine doses – including both primary series and booster shots – had been administered, positioning it among the largest immunization drives worldwide. Impressively, approximately 95% of the eligible population (aged 12 and above) received at least one dose, while 88% achieved full vaccination status, reflecting the strength and reach of India's healthcare delivery system. The campaign prominently featured two domestically developed vaccines: Covishield, produced by the Serum Institute of India using a viral vector platform, and Covaxin, an inactivated whole-virion vaccine developed by Bharat Biotech, showcasing India's advanced biotechnological capabilities. Subsequently, the program expanded to incorporate additional vaccines, such as Sputnik V, Moderna, Johnson & Johnson, and ZyCoV-D, thereby broadening protective coverage. A comprehensive study published in The Lancet in June 2022 estimated that India's vaccination efforts averted approximately 4.2 million deaths between December 2020 and December 2021. This monumental public health intervention not only curtailed viral transmission and mitigated disease severity but also cemented India's stature as a global hub for vaccine production, distribution, and immunization innovation, contributing substantially to worldwide pandemic control [35].

The two principal vaccines deployed in India's COVID-19 immunization initiative – Covishield and Covaxin – exemplify the country's scientific and manufacturing prowess. Their defining characteristics are summarized below.

Covaxin (Bharat Biotech) – India's First Indigenous COVID-19 Vaccine

In collaboration with the Indian Council of Medical Research (ICMR), Bharat Biotech developed India's first indigenous COVID-19 vaccine, employing a whole inactivated virus platform. This vaccine triggers a comprehensive immune response by presenting the immune system with multiple viral antigens, offering broad-spectrum protection against SARS-CoV-2. Clinical data demonstrated an efficacy rate of approximately 81% against symptomatic COVID-19 infections during the period preceding India's second pandemic wave, underscoring its critical role in national disease mitigation efforts. Importantly, the vaccine has maintained efficacy against key viral variants, such as Beta and Delta, showcasing resilience against emerging mutations. The safety profile has been favorable, with low incidences of serious adverse effects, facilitating its authorization for pediatric immunization – a vital step toward broader population coverage.

© STM Journals 2026. All Rights Reserved

With standard refrigeration requirements (2–8°C), this vaccine circumvents the logistical challenges posed by ultra-cold storage vaccines, enabling efficient distribution across diverse geographic and resource-limited settings. This practical advantage has been instrumental in expanding vaccine reach throughout India, including remote and underserved areas. By bolstering indigenous vaccine manufacturing capacity, Bharat Biotech's vaccine diminishes dependency on global supply chains and fortifies India's position as a prominent global vaccine hub. Although breakthrough infections have been observed, the vaccine remains a key tool in preventing severe disease, hospitalizations, and mortality, affirming its continued significance in controlling COVID-19 within the country. This achievement highlights India's rapid progress in vaccine research and development, reflecting its growing technological capabilities and commitment to addressing global health challenges through innovation and self-reliance [41].

Covishield – Adenoviral Vector-Based COVID-19 Vaccine

Covishield is a recombinant viral vector vaccine that utilizes a replication-deficient chimpanzee adenovirus engineered to carry the genetic sequence for the SARS-CoV-2 spike (S) protein. Upon administration, this vaccine induces host cells to express the spike protein, eliciting a robust immune response that equips the body to recognize and neutralize the virus upon future exposure. This mechanism has proven effective in reducing the severity and transmission of COVID-19 infections [42].

Central to the unparalleled scale and efficiency of India's COVID-19 immunization campaign was the Co-WIN digital platform. Developed as an extension of the electronic Vaccine Intelligence Network (eVIN), Co-WIN enabled streamlined beneficiary registration, appointment scheduling, real-time vaccine stock monitoring, and digital certification issuance. The platform successfully registered over 847 million individuals, ensuring equitable vaccine access across diverse demographics via multiple identification options. Its transparency and efficiency minimized vaccine wastage and ensured optimal distribution across India's vast and varied population [43]. Together with the deployment of highly effective, affordable vaccines – such as Covishield and Covaxin – both characterized by strong immunogenicity and low incidence of adverse effects – India's vaccination campaign became one of the largest and most successful worldwide. The success of Co-WIN showcased India's capacity to manage large-scale healthcare logistics through a scalable, data-driven framework, setting a precedent for future public health endeavors focused on accessibility, affordability, and safety. India's vaccine innovation journey spans over a century, marked by pioneering developments from the Plague vaccine to cutting-edge COVID-19 vaccines. Indian pharmaceutical companies and research institutions have continually contributed to both national and global health security by developing vaccines targeting endemic and emerging infectious diseases. The accompanying table 1 summarizes key vaccines developed in India, highlighting their timelines, modes of administration, distinctive features, and their crucial roles in advancing public health outcomes worldwide.

Table 1. Shows major vaccines developed: timeline, features, and administration.

S. N.	Vaccine name	Year of development	Mode of administration	Features	Ref.
1.	Rotovac	2015	Oral Drops	India's first indigenous rotavirus vaccine, prevents severe diarrhea.	[44]
2.	Typbar TCV (Typhoid Conjugate Vaccine)	2013	Intramuscular Injection	Provides long-term immunity against typhoid fever.	[45]
3.	Covaxin	2020	Intramuscular Injection	India's first indigenous COVID-19 vaccine, inactivated virus-based.	[46]
4.	ZyCoV-D	2020	Needle-Free (Intradermal)	India's first DNA-based COVID-19 vaccine, uses a three-dose regimen.	[47]
5.	Corbevax	2021	Intramuscular Injection	Protein subunit vaccine, developed as a low-cost COVID-19 vaccine.	[48]

© STM Journals 2026. All Rights Reserved

6.	iNCOVACC	2022	Intranasal	India's first intranasal COVID-19 vaccine, stimulates mucosal immunity.	[49]
7.	Hillchol	2022	Oral Drops	India's oral cholera vaccine, prevents cholera outbreaks.	[50]

Thus, through a combination of indigenous innovation and collaboration with international health organizations, India has made significant strides in creating vaccines that cater to both endemic diseases and pandemic responses. The vaccines listed in the table illustrate not only India's technological prowess but also its dedication to providing affordable and accessible health solutions to people worldwide. As the country continues to lead in vaccine development and distribution, its role in shaping the future of global health remains indispensable.

INDIA'S STRATEGIC PARTNERSHIPS IN VACCINE DEVELOPMENT AND DISTRIBUTION

India has long earned the title of the "pharmacy of the world," a stature that was further solidified during the COVID-19 pandemic. Beyond being a global manufacturing hub, India distinguished itself as a leader in vaccine research and development, conducting large-scale clinical trials, and facilitating equitable vaccine distribution across diverse populations. Through strategic alliances with international organizations, governments, and biotech innovators, India exemplified the impact of synergistic public–private partnerships and international collaboration. This confluence of indigenous scientific innovation and global cooperation was pivotal in accelerating vaccine availability and accessibility worldwide. The following section explores the critical partnerships and collaborative frameworks that empowered India's significant role in advancing global immunization initiatives.

Vaccine Manufacturing Powerhouses

India's emergence as a global vaccine manufacturing powerhouse is a testament to its advanced biotechnology ecosystem and the concerted efforts of leading pharmaceutical companies and research institutions. Equipped with state-of-the-art bioprocessing technologies and high-capacity manufacturing facilities, India produces a broad spectrum of vaccines that meet rigorous international quality and safety standards. This robust infrastructure has enabled India to manufacture billions of vaccine doses annually, establishing the country as a critical node in the global vaccine supply chain. India's vaccine manufacturing capabilities were thrust into the global spotlight during the COVID-19 pandemic, when rapid scaling of production became imperative. Indian manufacturers, leveraging recombinant DNA technology, cell culture platforms, and novel adjuvant systems, accelerated the development and distribution of vaccines such as Covishield (Oxford-AstraZeneca) and Covaxin (Bharat Biotech). These efforts not only safeguarded millions of Indian citizens but also significantly augmented global vaccine availability.

Integral to India's success is its seamless collaboration with global health bodies including the World Health Organization (WHO), GAVI, and UNICEF. These partnerships have facilitated streamlined regulatory approvals, technology transfer, and supply chain logistics, enabling timely vaccine deployment across low- and middle-income countries. Through strategic vaccine diplomacy initiatives, like "Vaccine Maitri" and participation in COVAX, India has championed equitable access to lifesaving immunizations, narrowing disparities in global health equity. Beyond volume, India's biotechnological innovations underpin its leadership role. Cutting-edge vaccine platforms – ranging from live attenuated, inactivated, recombinant subunit to virus-like particle (VLP) vaccines – reflect the country's depth in immunobiology and molecular engineering. Indian vaccine developers have integrated novel formulation approaches, such as thermostable vaccine candidates, which reduce cold chain dependencies and enhance vaccine reach in resource-limited settings.

© STM Journals 2026. All Rights Reserved

Collectively, these capabilities underscore India's position not merely as a vaccine manufacturer, but as a catalyst for global health resilience. By marrying biotechnological innovation with large-scale production and strategic international collaborations, India continues to advance global immunization goals, driving progress against infectious diseases worldwide.

Table 2. Provides a detailed catalog of licensed human vaccine manufacturing facilities in India, showcasing the nation's advanced capabilities in vaccine production.

S. N.	Name of vaccine unit	Licensed vaccines
1.	Bharat Biotech International Ltd, Hyderabad	Hib, Rabies, bOPV, mOPV, DTP+Hib+HepB, Typhoid, H1N1, Rotavirus, Inactivated JE, DTP+HepB+Hib (Liquid).
2.	Biological E., Hyderabad	DTP, TT, JE, HepB, DTP+HepB+Hib (Liquid & Lyophilized), IPV.
3.	Biomed Pvt. Ltd, Ghaziabad	Hib, Meningococcal Polysaccharide, Rabies, Typhoid.
4.	Cadila Healthcare, Ahmedabad	Rabies, H1N1, Typhoid, Tetravalent Influenza.
5.	Cadila Pharmaceuticals Ltd., Ahmedabad	H1N1 VLPs Vaccine.
6.	Chiron Behering, Gujarat	Rabies vaccine.
7.	Dano Vaccine & Biological Pvt. Ltd., Hyderabad	TT.
8.	Green Signal BioPharma Ltd, Chennai	BCG Vaccine.
9.	Panacea Biotec, Himachal Pradesh	DTP, HepB, Hib, IPV, H1N1, bOPV.
10.	Ranbaxy Lab, Bangalore	Typhoid, Hib Conjugate vaccine.
11.	Serum Institute of India, Pune	DTP, TT, HepB, MMR, BCG, Rabies, IPV, H1N1, Meningococcal, Measles, Influenza.
12.	Shantha Biotechnics, Hyderabad & Medak	DTP, HepB, Hib, TT, Oral Cholera vaccine, IPV.
13.	Sanofi Pasteur India Pvt Ltd, Navi Mumbai	Hib, Typhoid, HepA, Yellow Fever, Rabies, Meningococcal, IPV.
14.	GSK Asia Pvt. Ltd., Nashik	Pneumococcal, Haemophilus influenza vaccine.
15.	BIBCOL, Bulandshahr, Uttar Pradesh	bOPV.
16.	Haffkine, Mumbai	mOPV, bOPV.
17.	Human Biologicals Institute, Hyderabad & Udhagamandalam	Rabies, DTP, TT, HepB.
18.	BCG Vaccine Lab, Guindy, Chennai	BCG, Tuberculin.
19.	Central Research Institute (CRI), Kasauli, HP	DTP, Yellow Fever, JE, TT, DT.
20.	Pasteur Institute of India, Coonoor, Tamil Nadu	DTP, TT, DT, Inactivated Rabies vaccine.

The following table 2 displayed above outlines the principal Indian pharmaceutical firms and research entities whose pioneering vaccine technologies and production capacities have been instrumental in shaping the global immunization landscape [51].

Strategic Partnerships

India's global health influence is anchored in its capacity for innovative vaccine development and robust international collaborations. A landmark achievement in this arena is the development of MenAfriVac in 2010 – a meningococcal A conjugate vaccine engineered by the Serum Institute of India (SII) in partnership with PATH and the World Health Organization (WHO). Utilizing advanced conjugate vaccine technology, MenAfriVac offers enhanced immunogenicity and unprecedented thermostability, maintaining efficacy without refrigeration for up to four days. This breakthrough facilitated widespread immunization campaigns in sub-Saharan Africa, where over 100 million individuals across ten countries received the vaccine by 2012, resulting in a substantial decline in meningitis A outbreaks and mortality. The success of MenAfriVac exemplifies India's ability to integrate biotechnology innovation with scalable manufacturing solutions to address pressing public health challenges in resource-limited settings. Additionally, PATH's collaboration in introducing the

© STM Journals 2026. All Rights Reserved

Japanese Encephalitis (JE) vaccine in India's 2006 immunization drive significantly lowered disease incidence, particularly safeguarding children in endemic regions through targeted immunoprophylaxis [52].

India's vaccine manufacturing leadership was dramatically reinforced during the COVID-19 crisis through the rapid technology transfer and large-scale production of the Oxford-AstraZeneca vaccine, branded as Covishield, by SII. This effort underscored India's proficiency in recombinant viral vector vaccine platforms and mass bioprocess engineering, making it the world's largest vaccine producer in volume. Initiatives, like COVAX and the government's "Vaccine Maitri" program, reflected India's commitment to global vaccine equity by supplying doses to numerous low- and middle-income countries, strategically counterbalancing geopolitical vaccine diplomacy. Further amplifying its global health diplomacy, India actively participates in the Quad Health Security Partnership alongside Australia, Japan, and the United States. Beyond the delivery of nearly 800 million COVID-19 vaccine doses via the Quad Vaccine Partnership, the alliance now emphasizes enhancing regional capacities for infectious disease surveillance, outbreak preparedness, and health system strengthening in the Indo-Pacific. These efforts include workforce training in epidemiology, expanding laboratory networks, and deploying data-driven public health interventions, reinforcing resilience against future pandemics [53].

Collectively, these multifaceted initiatives highlight India's emergence as a biotechnology powerhouse with a pivotal role in shaping global health governance. By combining advanced vaccine technologies, scalable manufacturing, and strategic international cooperation, India is redefining equitable healthcare access and global pandemic preparedness. These contributions not only mitigate disease burdens but also foster international solidarity, establishing a foundation for a more robust, inclusive, and technology-enabled global health architecture.

CHALLENGES IN DEVELOPMENT & DISTRIBUTION

India faces a range of complex challenges in vaccine development and distribution, which hinder the country's efforts to achieve widespread immunization. These challenges encompass not only issues in research and infrastructure but also public perception. Limited funding for research, a shortage of trained immunologists, and legal hurdles in clinical trials hamper vaccine development. On the distribution front, inadequate cold storage facilities, unreliable electricity, and difficult geographical terrain make it hard to ensure vaccines reach all regions, especially remote areas. Furthermore, vaccine misinformation, hesitancy, and a lack of trust in vaccine safety, fueled by fear and poor communication, further complicate efforts. These multifaceted challenges require coordinated strategies to overcome, ensuring more effective vaccine delivery and public acceptance [54].

Vaccine Development Challenges

- *Insufficient Funding for Advanced Vaccine Research:* India's current investment in vaccine R&D remains inadequate to support cutting-edge innovation such as next-generation vaccine platforms (e.g., mRNA, viral vectors, protein subunits). The funding gap limits exploration into novel adjuvants, delivery systems, and thermostable formulations essential for enhancing immunogenicity and accessibility in tropical climates.
- *Shortage of Specialized Immunological Expertise:* The country faces a critical shortage of highly trained immunologists, vaccinologists, and molecular biologists. This limits deep mechanistic understanding of host–pathogen interactions, immune correlates of protection, and antigen design, which are prerequisites for developing vaccines against emerging and complex pathogens.
- *Absence of Lifecycle Immunization Frameworks:* While India has demonstrated success in targeted campaigns, such as polio eradication, it lacks a robust integrated immunization strategy that covers diverse population cohorts across the lifespan – from infancy through adulthood and elderly care – thereby limiting sustained immunity and herd protection at the population level.
- *Regulatory and Legal Barriers in Clinical Development:* Stringent and evolving regulatory norms for clinical trials, compounded by legal challenges and prolonged approval timelines, hinder rapid translation of promising vaccine candidates into licensed products. These bottlenecks increase costs and discourage innovation.

© STM Journals 2026. All Rights Reserved

- *Intellectual Property and Licensing Constraints:* Complexities related to patent rights, technology transfer restrictions, and licensing agreements inhibit local vaccine manufacturing capacity expansion. This delays affordable vaccine availability and compromises self-sufficiency in public health emergencies.
- *Global Intellectual Property Politics Impacting Access:* The resistance by some global stakeholders to temporarily waive intellectual property protections during pandemics, like COVID-19, has exacerbated inequities, limiting India's ability to produce and supply vaccines affordably to its vast population and neighboring countries.
- *Threat of Vaccine Counterfeiting and Quality Control Issues:* The presence of counterfeit or substandard vaccines circulating in the market poses severe risks, including treatment failure and adverse events, ultimately eroding public confidence in immunization programs.

Vaccine Distribution Challenges

- *Inadequate Cold Chain Infrastructure and Maintenance:* A major logistical hurdle is the insufficient availability and maintenance of cold storage facilities essential for preserving vaccine potency, especially in rural, tribal, and remote areas where ambient temperatures can exceed vaccine stability thresholds.
- *Unreliable Electricity and Energy Supply:* Frequent power outages and inconsistent electricity supply disrupt the functioning of refrigeration units, jeopardizing vaccine integrity. Alternative energy solutions and backup systems are often lacking in underserved regions.
- *Geographical and Transportation Barriers:* India's vast and varied terrain, including mountainous and forested areas with poor road connectivity, creates significant difficulties in timely vaccine delivery. This limits coverage and increases the risk of missed or delayed vaccinations.
- *Misinformation, Vaccine Hesitancy, and Public Distrust:* The spread of misinformation via social media and traditional channels generates vaccine hesitancy and refusal. This phenomenon is aggravated by inadequate culturally sensitive communication, lack of transparent data sharing on vaccine safety and efficacy, and historical mistrust of health authorities.

Addressing these multilayered challenges demands a comprehensive, interdisciplinary strategy: increased and targeted funding to fuel innovative vaccine R&D; capacity building through specialized training programs to bridge immunology expertise gaps; regulatory reforms to streamline clinical development; strengthening intellectual property frameworks that balance innovation incentives with public health needs; robust investments in cold chain and energy infrastructure; enhanced logistical planning to overcome geographical barriers; and, critically, transparent, culturally tailored public engagement to counter misinformation and build vaccine confidence. This integrative approach will not only optimize vaccine development pipelines and distribution networks but also promote equitable immunization access, ensuring India's preparedness for current and future infectious disease threats while consolidating its global leadership in vaccine innovation and public health.

STRATEGIES TO STRENGTHEN VACCINE DEVELOPMENT AND DISTRIBUTION IN INDIA

India has made remarkable strides in vaccine development and immunization coverage, yet critical challenges persist that impede accelerated progress in this vital domain. Constraints, such as underfunded vaccine R&D pipelines, a shortage of specialized biotech and clinical research talent, complex regulatory environments, intellectual property restrictions, fragile cold chain logistics, and operational challenges in reaching underserved populations, remain significant hurdles. Compounding these is pervasive vaccine hesitancy driven by misinformation and a deficit of transparent, science-based communication, which undermines public confidence. Addressing these multifactorial issues demands a sophisticated, integrative strategy rooted in cutting-edge innovation, human capital development, infrastructural modernization, and proactive community engagement [54].

- Catalyzing transformative advances in vaccine innovation requires sustained, strategic investments from both public and private sectors, alongside targeted fiscal incentives and enhanced public–private partnerships. Prioritizing R&D for vaccines tailored to India's unique disease burden – including emerging infectious diseases and neglected tropical infections – will solidify India's position as a

© STM Journals 2026. All Rights Reserved

global vaccine powerhouse. Concurrently, empowering a new generation of biotech professionals through specialized training programs and upskilling initiatives will expand the nation's capacity for advanced vaccine research, development, and deployment.

- Transparent, culturally nuanced communication frameworks are indispensable for countering vaccine misinformation and fostering societal trust. Disseminating rigorous clinical trial data and real-world vaccine effectiveness in accessible formats will enhance vaccine acceptance and adherence.
- The legal framework enabling compulsory licensing under the Indian Patent Act must be leveraged judiciously during health crises to expedite domestic production of critical vaccines and biologics, ensuring affordability and reducing external dependencies.
- Robust cold chain infrastructure and strategically managed vaccine stockpiles are imperative for maintaining antigen stability and enabling rapid mobilization in outbreak scenarios. Investing in next-generation cold storage technologies and integrating real-time digital monitoring can dramatically enhance supply chain resilience.
- Cutting-edge digital innovations, including blockchain-enabled traceability and IoT-powered logistics management, can revolutionize vaccine supply chains by ensuring end-to-end transparency, preventing counterfeiting, and reinforcing stakeholder confidence.
- Fostering a comprehensive ancillary manufacturing ecosystem – encompassing the production of syringes, vials, adjuvants, excipients, and cold chain equipment – will underpin national self-sufficiency in vaccine manufacturing and safeguard critical supply chains against global disruptions [54].

Thus, India's pathway to consolidating its leadership in global vaccine innovation and equitable access lies in deploying a synergistic approach combining scientific excellence, workforce empowerment, agile regulatory mechanisms, infrastructure fortification, and transparent public engagement. By strategically advancing these dimensions, India can redefine the global vaccinology landscape, enhance pandemic preparedness, and ensure resilient, inclusive healthcare systems that safeguard millions worldwide.

CONCLUSION

India's influence on global vaccinology extends far beyond its status as a vaccine manufacturing powerhouse, embodying a profound commitment to cutting-edge scientific innovation, comprehensive public health strategies, and infectious disease eradication. By pioneering the development of affordable, high-efficacy vaccines and orchestrating expansive immunization campaigns, India has emerged as a cornerstone in strengthening global health security, especially in resource-limited settings. Its unparalleled expertise in vaccine research, development, and scalable production has not only saved millions of lives but also catalyzed transformative international collaborations that ensure equitable vaccine access across diverse populations.

In the face of evolving global health threats – ranging from emerging pathogens to antimicrobial resistance and shifting epidemiological patterns – India's strategic investment in advanced biotechnology, genomic research, and novel vaccine platforms is critical. Leveraging state-of-the-art manufacturing infrastructure and agile distribution networks, India is positioned to drive innovation in next-generation vaccines, including mRNA and vector-based technologies, while sustaining cost-effectiveness and broad accessibility. Furthermore, its commitment to immunization equity serves as a powerful model for reducing healthcare disparities, reinforcing resilient health systems, and mitigating pandemic risks worldwide.

As the nexus of scientific excellence and public health pragmatism, India continues to propel vaccine science forward through dynamic global partnerships and policy leadership. Its evolving role underscores a future where universal immunization is not merely aspirational but achievable – fortifying global preparedness and delivering transformative health outcomes for billions. This integrated approach epitomizes India's capacity to shape the trajectory of vaccinology, fostering a more equitable and resilient world.

© STM Journals 2026. All Rights Reserved

Future Directions

The COVID-19 pandemic has catalyzed a paradigm shift in India's pharmaceutical and healthcare landscape, unlocking unprecedented opportunities in vaccine innovation, biomanufacturing, and healthcare infrastructure development. Building upon India's established global leadership in syringe production, strengthening allied sectors, such as vial manufacturing, packaging, and cold chain logistics, is essential for creating a resilient supply ecosystem. The expansion and modernization of cold storage infrastructure – originally scaled for vaccine distribution – holds transformative potential for reducing post-harvest losses in agriculture and stabilizing food supply chains.

To bridge persistent healthcare disparities, particularly in underserved rural regions, India must continue enhancing frontline health delivery through the expansion of Primary Health Centers, Accredited Social Health Activists (ASHAs), and Anganwadi workers, thereby reinforcing community-based care. The pharmaceutical sector, invigorated by pandemic exigencies, is intensifying interdisciplinary research efforts, driving the discovery and development of Novel Chemical Entities (NCEs) that address emerging health challenges.

India's vaccinology expertise is advancing rapidly with breakthroughs in mRNA, viral vector, and protein subunit vaccine platforms. Concurrently, research into thermostable formulations and needle-free delivery systems promises to revolutionize vaccine accessibility and compliance. The integration of artificial intelligence in biomanufacturing processes and predictive analytics, alongside robust public–private partnerships and harmonized regulatory frameworks aligned with global standards, will be instrumental in scaling production to meet international demand.

Looking ahead, personalized vaccines targeting cancers and infectious diseases, coupled with novel interventions for neglected tropical diseases, such as dengue and tuberculosis, underscore India's commitment to comprehensive health innovation. The deployment of AI-powered disease surveillance and blockchain-enabled supply chain management will enhance transparency, traceability, and efficiency in vaccine distribution. Sustained emphasis on affordability and equitable access, particularly for low- and middle-income countries, remains pivotal to solidifying India's role as a global leader in immunization, pandemic preparedness, and holistic health security.

Together with our companion review, "Vaccines Through Time: Conventional Foundations and Next-Gen Innovations–Part 1, which provides a broader overview of the historical evolution of vaccines and emerging vaccine technologies, the present article completes a comprehensive two-part review on vaccinology, encompassing both the evolution of vaccine science and India's significant contributions to global vaccine innovation and public health [55].

Acknowledgment

VG acknowledges financial support from ICMR, Govt. of India (Grant BMI/12(116)/2021; ID 2021-6501). MG gratefully acknowledges Ms. Shreya Roy for her critical review and valuable feedback.

REFERENCES

1. Plotkin S. History of vaccination. Proc Natl Acad Sci U S A. 2014 Aug;111(34):12283–12287. doi: 10.1073/pnas.1400472111. Available from: https://doi.org/10.1073/pnas.1400472111.
2. INSEAD Africa Initiative [Internet]. INSEAD. 2026. Available from: https://www.insead.edu/insead-africa-initiative
3. Statista. Vaccines in India - pharmaceuticals industry. Statista. 2025. Available from: https://www.statista.com/outlook/hmo/pharmaceuticals/vaccines/india?currency=USD. Accessed 14 Apr 2025.

© STM Journals 2026. All Rights Reserved

4. Salalli R, Dange JR, Dhiman S, Sharma T. Vaccines development in India: Advances, regulation, and challenges. Clin Exp Vaccine Res. 2023 Jul;12(3):193–208. doi: 10.7774/cevr.2023.12.3.193.
5. Tahamtan A, Charostad J, Hoseini Shokouh SJ, Barati M. An overview of history, evolution, and manufacturing of various generations of vaccines. J Arch Mil Med. 2017;5:e12315.
6. Ministry of Health and Family Welfare. Annual report 2016–17: Organization and infrastructure. New Delhi: Ministry of Health and Family Welfare; 2018. Available from:https://main.mohfw.gov.in/sites/default/files/1201617.pdf.
7. Howard N, Walls H, Bell S, Mounier-Jack S. The role of National Immunisation Technical Advisory Groups (NITAGs) in strengthening national vaccine decision-making: A comparative case study of Armenia, Ghana, Indonesia, Nigeria, Senegal and Uganda. Vaccine. 2018;36(39):5536–5543. doi: 10.1016/j.vaccine.2018.07.046.
8. Sathiaraj E. Better nutrition for a better future. Geneva: James Lind Institute; 2021. Available from: https://www.jli.edu.in/blog/roles-and-responsibilities-ofcdsco.
9. Indian Council of Medical Research. Announcement: Indian Council of Medical Research reference list. New Delhi: Indian Council of Medical Research; 2017. Available from: http://www.icmr.nic.in/.
10. Kadam R, Karandikar S. Ethics committees in India: Facing the challenges. Perspect Clin Res. 2012;3(2):50–56. doi: 10.4103/2229-3485.96446.
11. World Health Organization (2009). Research ethics committees : basic concepts for capacity-building. World Health Organization. World Health Organization. Available: https://iris.who.int/handle/10665/44108
12. National Health Mission. Immunization: National Health Mission. Available from: https://nhm.gov.in.
13. Press Information Bureau. Shri J P Nadda launches pneumococcal conjugate vaccine (PCV) under universal immunization programme (UIP). 2017 May 30. Available from: https://pib.nic.in.
14. Patra N. Universal immunization programme in India: The determinants of childhood immunization [PDF]. Calcutta: Indian Statistical Institute; 2012.
15. Chatterjee S, Pant M, Haldar P, Aggarwal MK, Laxminarayan R. Current costs and projected financial needs of India's universal immunization programme. Indian J Med Res. 2016;143(6):801–808. doi: 10.4103/0971-5916.192073.
16. Jafari H, et al. Progress Toward Polio Eradication in India. Journal of Infectious Diseases. 2014;210(Suppl 1):S296–S303.
17. UNICEF. Social Mobilization Network for Polio Eradication in India: Lessons Learned. New Delhi: UNICEF; 2013
18. Summan, Amit; Nandi, Arindam; Deo, Sarang; Laxminarayan, Ramanan (2021). "Improving vaccination coverage and timeliness through periodic intensification of routine immunization: evidence from Mission Indradhanush". *Annals of the New York Academy of Sciences*. 1502 (1): 110-120
19. Press Information Bureau. Intensified Mission Indradhanush (IMI) 5.0 campaign concludes all three rounds on 14 Oct 2023. Available from: https://pib.gov.in/PressReleasePage.aspx?PRID=1966931.
20. The Hindu Business Line. Vaccine Maitri: A sanjeevini for the world. The Hindu Business Line 2021 Mar 4. Available: https://www.thehindubusinessline.com/news/variety/vaccine-maitri-a-sanjeevini-for-the-world/article62178717.ece
21. Press Trust of India. 162.9 million Covid vaccine doses supplied to 98 countries: Govt [Internet]. bsindia. Business Standard; 2022. Available from: https://www.business-standard.com/amp/article/current-affairs/162-9-million-covid-vaccine-doses-supplied-to-98-countries-govt-122031501045_1.htm
22. Coronavirus: India temporarily halts Oxford-AstraZeneca vaccine exports," BBC News, Mar. 24, 2021. [Online]. Available : https://www.bbc.com/news/world-asia-india-56513371 .

© STM Journals 2026. All Rights Reserved

23. COVID vaccine: India to resume vaccine exports from October," BBC News, Sep. 21, 2021. [Online]. Available: https://www.bbc.com/news/world-asia-india-58634570
24. India pledges support to UN to ensure Syria gets COVID vaccines," NDTV, Mar. 23, 2021. [Online]. Available: https://www.ndtv.com/india-news/india-pledges-support-to-un-to-ensure-syria-gets-covid-vaccines-2382459. .
25. Mint. India's 'gift' to UN peacekeepers: 200,000 COVID vaccine doses. Mint. 2021 Mar 26.
26. Ravelo JL. The evolution of global health's 'best-kept secret'. Devex. 2014 Nov 10.
27. World Health Organization. GAVI – The global alliance for vaccines and immunizations. WHO. 2022 Apr 5.
28. Ikilezi G, Augusto OJ, Dieleman JL, Sherr K, Lim SS. Effect of donor funding for immunization from Gavi and other development assistance channels on vaccine coverage. Vaccine. 2020;38(3):588–596. doi: 10.1016/j.vaccine.2019.10.057.
29. Jaupart P, Dipple L, Dercon S. Has Gavi lived up to its promise? BMJ Glob Health. 2019;4(6):e001789. doi: 10.1136/bmjgh-2019-001789.
30. Tsai FJ, Lee H, Fan VY. Perspective and investments in health system strengthening of Gavi, the vaccine alliance. Int Health. 2016;8(4):246–252. doi: 10.1093/inthealth/ihv063.
31. T. Paulson, "Doctors Without Borders criticizes Gates-backed global vaccine strategy," Humanosphere, May 15, 2012. [Online]. Available: https://web.archive.org/web/20211103200819/https://www.humanosphere.org/global-health/2012/05/doctors-without-borders-criticizes-gates-backed-global-vaccine-strategy/
32. Doctors Without Borders – USA. Pneumococcal vaccine is launched in Africa, but are donors getting a fair deal from companies? Available from: https://www.doctorswithoutborders.org.
33. Storeng KT. The GAVI alliance and the 'Gates approach' to health system strengthening. Glob Public Health. 2014;9(8):865–879. doi: 10.1080/17441692.2014.940362.
34. Directorate General of Health Services. National tuberculosis elimination programme. Ministry of Health and Family Welfare, Government of India. Available from: https://dghs.mohfw.gov.in/national-tuberculosis-elimination-programme.php.
35. Ministry of Health and Family Welfare, Government of India. India's immunization drive: A commitment to universal vaccine coverage and health equity. Press release; Apr 2025.
36. Havisure – India's first indigenously developed hepatitis A vaccine," PWOnlyIAS, Jan. 22, 2024. [Online]. Available: https://pwonlyias.com/current-affairs/havisure-vaccine/
37. Shantha Biotechnics. Shanvac-B. Available from: https://shanthabiotech.com/shanvac_b.asp.
38. Serum Institute of India Pvt Ltd. Pentavac (PFS/SD) – diphtheria, tetanus, pertussis, hepatitis B and Haemophilus type b conjugate vaccine. Available from: https://www.seruminstitute.com/product_ind_pentavac.php.
39. Serum Institute of India. CERVAVAC – quadrivalent human papilloma virus vaccine. Available from: https://www.seruminstitute.com/product_ind_cervavac.php.
40. Bharat Biotech. ROTAVAC – first rota virus vaccine manufacturer. Available from: https://www.bharatbiotech.com/rotavac.html.
41. Behera P, Singh AK, Subba SH, Mc MA, Sahu DP, Chandanshive PD, et al. Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India. Hum Vaccin Immunother. 2022;18(1):2034456. doi: 10.1080/21645515.2022.2034456.
42. Serum Institute of India Pvt Ltd. COVISHIELD FAQs. 2021 Jul 5. Available from: https://www.seruminstitute.com/health_faq_covishield.php.
43. Press Information Bureau. Union health minister lists achievements of the union health ministry in the first 100 days of the new government. 2024 Sep 20. Available: https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=1732812&reg=48&lang=2.
44. N. P. Nair et al., "Impact of the indigenous rotavirus vaccine Rotavac in the Universal Immunization Program in India during 2016–2020," Nature Medicine, 2025. [Online]. Available: https://www.nature.com/articles/s41591-025-03998-9
45. Bharat Biotech. COVAXIN. Available from: https://www.bharatbiotech.com/covaxin.html.
46. Wikipedia. ZyCoV-D. Available from: https://en.wikipedia.org/wiki/ZyCoV-D.

© STM Journals 2026. All Rights Reserved

47. Dey A, Chozhavel Rajanathan TM, Chandra H, Pericherla HP, Kumar S, Choonia HS, et al. (July 2021). "Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models". Vaccine. 39 (30): 4108–4116. doi:10.1016/j.vaccine.2021.05.098. ISSN 0264-410X. PMC 8166516. PMID 34120764
48. Thuluva S, Paradkar V, Gunneri SR, Yerroju V, Mogulla R, Turaga K, et al. (August 2022). "Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials". eBioMedicine. 83 104217. doi:10.1016/j.ebiom.2022.104217. PMC 9372721. PMID 35970020
49. iNCOVACC - Intranasal Vaccine For Covid-19 | Bharat Biotech [Internet]. Bharatbiotech.com. 2025. Available from: https://www.bharatbiotech.com/intranasal-vaccine.html
50. Hillchol® | Hillchol Vaccine Manufacturer in India | Bharat Biotech [Internet]. Bharatbiotech.com. 2018. Available from: https://www.bharatbiotech.com/hillchol.html
51. Ministry of Science and Technology, Government of India. List of licensed human vaccine manufacturing facilities in India. India Science, Technology & Innovation Portal. Available from: https://www.indiascienceandtechnology.gov.in.
52. Seattle Post-Intelligencer (May 21, 2007). "PATH, influential global health office, marks 30 years". Archived from the original on June 27, 2021. Retrieved February 13, 2013. Available: PATH, influential global health office, marks 30 years
53. Indo-Pacific Health Security. Quad vaccine partnership. Department of Foreign Affairs and Trade (DFAT). Available from: https://indopacifichealthsecurity.dfat.gov.au.
54. Vision IAS. India's vaccination drives: strategy, obstacles and opportunities. Available from: https://cdn.visionias.in/value_added_material/8d9e6-indias-vaccination-drives_strategy-obstacles-and-opportunities.pdf.
55. Maitry Goel, Vibha Gupta. Vaccines Through Time: Conventional Foundations and Next-Gen Innovations–Part 1. Research and Reviews: A Journal of Microbiology and Virology. 2026; 16(01):53-70.
Available from: https://journals.stmjournals.com/rrjomv/article=2026/view=238848

© STM Journals 2026. All Rights Reserved